Adjusted daily closes · 252 observations · as of Nov 6, 2026
Historical data, not a forecast
1 month
+13.0%
3 months
+11.0%
6 months
+40.7%
1 year
+49.9%
Year to date
+43.5%
52-week range
$307.11 – $478.48
Fundamental snapshot
Latest reported period: Sep 30, 2026
Sharadar reported data
Market cap
$249.05B
P/E
26.5
P/B
17.4
P/S
6.4
Revenue
$38.9B
Net income
$9.39B
Diluted EPS
17.25
Gross margin
70.90%
Net margin
24.10%
Return on equity
85.60%
Total debt
$54.01B
Cash
$13.19B
Free cash flow
$9.58B
Latest eight reported quarters
Reported quarterly values, newest first
Period
Revenue
Net income
Gross margin
Net margin
Free cash flow
Sep 30, 2026
$10.37B
$3.86B
73.10%
37.30%
$3.65B
Jun 30, 2026
$10.05B
$2.38B
72.00%
23.60%
$3.49B
Mar 31, 2026
$8.62B
$1.82B
68.20%
21.10%
$1.48B
Dec 31, 2025
$9.87B
$1.33B
69.80%
13.50%
$961M
Sep 30, 2025
$9.56B
$3.22B
67.80%
33.70%
$4.25B
Jun 30, 2025
$9.18B
$1.43B
67.20%
15.60%
$1.91B
Mar 31, 2025
$8.15B
$1.73B
63.60%
21.20%
$980M
Dec 31, 2024
$9.09B
$627M
65.70%
6.90%
$4.4B
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Xencor, Inc. reported its financial results for the third quarter ended September 30, 2026, highlighting progress across its clinical-stage pipeline for cancer and autoimmune diseases. Key updates include compelling clinical data for XmAb819 in advanced clear cell renal cell carcinoma, upcoming presentations for plamotamab in rheumatoid arthritis, and on-track development for TL1A-targeting programs XmAb942 and XmAb412. The company also detailed significant milestones achieved with partners Amgen, Astellas, and Zenas BioPharma, and reported a net income of $39.4 million for the quarter.
Regeneron Pharmaceuticals reported strong third-quarter 2026 results with US$5.1 billion in revenue and US$1.95 billion in net income, exceeding expectations. The company also affirmed its quarterly dividend and continued share buybacks, while expanding its BARDA agreement for Ebola treatment and presenting positive data for Libtayo in skin cancer. These results reinforce Regeneron's earnings engine, with a focus on late-stage pipeline execution and competition in eye care, and analysts anticipate continued revenue and earnings growth through 2029.